



## Omne Possible announces investment from eureKARE SA

**Leuven, Belgium, and Basel, Switzerland – 18 May 2021:** Omne Possible ("the Company"), a global synthetic biology company pioneering the XNA revolution, announced today the entry of eureKARE SA into its capital.

eureKARE SA is a recently founded company focused on financing and building next generation biotechnology companies in the disruptive fields of the microbiome and synthetic biology. eureKARE is guided by influential founder, Alexandre Mouradian, along with a pan-European team led by renowned biotech expert Rodolphe Besserve.

Omne Possible combines the key disciplines of XNA development, including chemical synthesis, genetics, directed evolution of enzymes and genomes, automated design of molecules, and bioproduction pathways. It has established an R&D innovation centre in Leuven, Belgium, to focus on XNA chemistry, and a second R&D hub in Basel, Switzerland, dedicated to XNA genetics. It intends to grow rapidly through a combination of in-house development and industrial collaborations.

**Patrice Garnier, President and Chief Executive Officer of Omne Possible, said:** "This investment will not only help us develop our XNA related technologies, but also launch the development of XNA polymers for information storage and XNA building blocks for improved messenger therapeutics."

**Rodolphe Besserve, Chief Executive Officer of eureKARE, added:** "Omne Possible is an exciting new venture in synthetic biology, which has the potential to radically disrupt many fields, including those of data storage and messenger RNA therapeutics. We are strongly convinced that it will be part of tomorrow's global biotech leaders due to its proprietary technologies and team intelligence."

-End-

### About Omne Possible

Omne Possible is a pioneering, global technological leader in XNA, creating customizable structures to outperform current DNA and RNA technologies. Its goal is to harness the transformative power of XNA in areas including healthcare, information technology and smart materials. The Company's initial focus is on development of XNA polymers for information storage and XNA building blocks for improved messenger therapeutics. Omne Possible has R&D hubs in Leuven, Belgium, and Basel, Switzerland. It was founded by leading European synthetic biologists and is supported by a world class scientific advisory board.

For more information, please visit [www.omnepossible.com](http://www.omnepossible.com)

### About eureKARE

eureKARE is a pioneering new company focused on financing and building next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology.

eureKARE has a two-step investment approach to deliver long-term value creation. The Company supports transformational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology). The Company also intends to invest in more mature biotech companies and will systematically propose to offer some liquidity to early investors, thereby addressing a critical need in the European biotech field. Guided by its influential founder, Alexandre Mouradian, and a pan-European team, eureKARE has a rapidly growing portfolio of companies that have the potential to disrupt the life sciences industry. eureKARE is headquartered in Luxembourg, with a presence in France & Belgium.

For more information visit: <https://eurekare.eu>

## **Contact**

### **Omne Possibile**

Patrice Garnier, Chief Executive Officer

[info@omnepossibile.com](mailto:info@omnepossibile.com)

### **eureKARE SA**

Marina Shapochnik, Head Investor Relations

[marina.shapochnik@eurekare.eu](mailto:marina.shapochnik@eurekare.eu)

### **Consilium Strategic Communications**

Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs

+44 (0) 203 709 5000

[eurekare@consilium-comms.com](mailto:eurekare@consilium-comms.com)